Another suit has been added to the Pradaxa multidistrict litigation. This one involves a man who took the anticoagulant drug for less than six months and was then hospitalized for more than a week. His 10-day hospitalization was caused by internal bleeding that he believes was caused by his use of Pradaxa. A product liability suit alleging such things was filed in late August of this year in the Northern District of Illinois, but was soon transferred to the Southern District of Illinois to join other litigation against the drug and its manufacturer.
Currently, there are about 80 lawsuits included in the multidistrict litigation. When a multidistrict litigation is enacted, it is to ensure that there are no conflicting rulings or inconsistent settlements. The judicial process is streamlined by combining discovery and other pretrial proceedings. Any common factors in the suits are addressed at once rather than separately, saving time and expenses for all parties involved.
In addition to the Illinois man’s allegations of product liability, his suit insists that the drug and its manufacturer caused him personal injury due to negligence. His case began when he was prescribed Pradaxa by his physician in October 2011. He began consuming the drug on Oct. 27 and on March 11, 2012, he began suffering from internal bleeding.
The manufacturer of the drug is Boehringer Ingelheim Pharmaceuticals and this man is not the first person to sue after suffering from internal bleeding. The U.S. Food and Drug Administration has reported that thousands of unexpected and adverse events have occurred due to the consumption of Pradaxa and more than 500 deaths have been linked to the drug. This may mean that many suits will be filed in the multidistrict litigation.
Pradaxa has been on the market since 2010 when it was marketed as a substitute to Coumadin, which requires that patients using it restrict their diets.
Source: Injury Lawyer News, “Plaintiff Hospitalized For 10 Days Due to Pradaxa Internal Bleeding,” Tracy Ray, Oct. 14, 2012